Swissmedic and Swiss Red Cross Present National Haemovigilance Data Showing Favourable Safety Profile for INTERCEPT-Treated

  Swissmedic and Swiss Red Cross Present National Haemovigilance Data Showing
  Favourable Safety Profile for INTERCEPT-Treated Platelet Components

Business Wire

CONCORD, Calif. -- April 03, 2013

Cerus Corporation (NASDAQ: CERS) announcedtoday the results of a
haemovigilance study reflecting two years of experience with routine
transfusion of 62,500 INTERCEPT-treated platelet components recently presented
by Swissmedic and the Swiss Red Cross at the 15^th International
Haemovigilance Seminar (IHS) in Brussels, Belgium.

“Swiss haemovigilance data from transfusion of INTERCEPT-treated platelet
components support the favourable safety profile of this pathogen inactivated
blood product compared with conventional platelets,” said Dr. Markus Jutzi,
Haemovigilance, Swissmedic, Swiss Agency of Therapeutic Products. “As
expected, in routine use, we observed that INTERCEPT-treated platelet
components prevented septic transfusion reactions. Furthermore, we detected no
increased risk for pulmonary adverse events. The introduction of the INTERCEPT
procedure also obviated the need for gamma irradiation.”

The INTERCEPT Blood System for platelets was introduced into routine use in
Switzerland in 2011, where reporting of transfusion-related adverse events is
mandatory. The cumulative haemovigilance data allowed for comparison of risks
associated with transfusion of conventional platelet components (during
2009-2011) and INTERCEPT-treated platelet components (during 2011-2012).

As presented at IHS, Dres. Rüesch, Jutzi and colleagues observed no change in
platelet or red blood cell utilization between the two periods. There were
fewer reports of non-infectious transfusion reactions in general (1:400) as
well as of severe (grade 3, 4) transfusion reactions (1:10,000) with
INTERCEPT-treated platelet components compared to conventional platelet
components (1:300 and 1:3,000, respectively). There were no instances of
septic reactions reported with INTERCEPT-treated platelet components, compared
to 4 septic reactions, including 1 fatality, with conventional platelet
components. Additionally, fewer and less severe transfusion reactions with
respiratory symptoms were reported for INTERCEPT-treated platelet components.

“We are very pleased by the improvements in transfusion safety documented by
the Swiss haemovigilance data after the adoption of the INTERCEPT Blood System
for platelets, and these results are consistent with the 6-year experience in
France reported by the ANSM haemovigilance system,” said Dr. Laurence Corash,
Cerus’ chief medical officer. “Cerus’ goal is to enable transfusion services
to deliver safe and effective blood products to patients, and we are proud to
work with countries such as Switzerland in this effort.”

The poster presentation (“Two years experience with pathogen inactivation for
platelet concentrates in Switzerland”) is available for download on the
Swissmedic website at
http://www.swissmedic.ch/marktueberwachung/00159/00160/00437/index.html.

The poster abstract has been published as P-11 in Blood Transfusion,
Supplement No. 1, February 2013, ISSN 1723-2007 and is available for download
at http://www.bloodtransfusion.it/scarica.aspx?tipo=A&id=002454&riv=81.

ABOUT CERUS

Cerus Corporation is a biomedical products company focused on enhancing blood
safety. The INTERCEPT system is designed to reduce the risk of
transfusion-transmitted diseases by inactivating a broad range of pathogens
such as viruses, bacteria and parasites that may be present in donated blood.
The nucleic acid targeting mechanism of action enables INTERCEPT treatment to
inactivate established transfusion threats, such as hepatitis B and C, HIV,
West Nile virus and bacteria, and is designed to inactivate emerging pathogens
such as influenza, malaria and dengue. Cerus currently markets and sells the
INTERCEPT Blood System for both platelets and plasma in Europe, the
Commonwealth of Independent States, the Middle East and selected countries in
other regions around the world. In the United States, Cerus is seeking
regulatory approval of the INTERCEPT Blood System for plasma, and is in the
process of determining the application shell for a potential regulatory
submission for the INTERCEPT Blood System for platelets. The INTERCEPT Blood
System for red blood cells is in clinical development. See
http://www.cerus.com for more information.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

Contact:

Cerus Corporation
Lainie Corten, 925-288-6319
Sr Director, Global Marketing & Investor Relations